BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35646685)

  • 21. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
    Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
    Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.
    Li Y; Li Y; Zhang H; Shi R; Zhang Z; Liu H; Chen J
    BMC Pulm Med; 2021 Jun; 21(1):190. PubMed ID: 34090412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcinoma and Non-Small Cell Lung Cancer.
    Wang Z; Liu X; Till B; Sun M; Li X; Gao Q
    Front Immunol; 2018; 9():1513. PubMed ID: 30026742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-Bet Mediated Anti-Neoplastic Effects of Dendritic Cell-Cytokine Induced Killer Cells in vitro.
    Miao L; Run-Ming J; Yi J
    Iran J Pediatr; 2012 Mar; 22(1):43-51. PubMed ID: 23056858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
    Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway.
    Pu J; Sharma A; Liu T; Hou J; Schmidt-Wolf IG
    Clin Transl Immunology; 2024; 13(3):e1500. PubMed ID: 38529413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt's lymphoma.
    Ge F; Wang Y; Sharma A; Yang Y; Liu H; Essler M; Jaehde U; Schmidt-Wolf IGH
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors.
    Vaseq R; Sharma A; Li Y; Schmidt-Wolf IGH
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials.
    Lv Y; Zhao H; Liu S; Meng Y; Yu W; Liu T; Sun Q; Shen M; Ren X; Liu L
    J Leukoc Biol; 2024 Feb; ():. PubMed ID: 38373017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
    Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
    Sang J; Acquaviva J; Friedland JC; Smith DL; Sequeira M; Zhang C; Jiang Q; Xue L; Lovly CM; Jimenez JP; Shaw AT; Doebele RC; He S; Bates RC; Camidge DR; Morris SW; El-Hariry I; Proia DA
    Cancer Discov; 2013 Apr; 3(4):430-43. PubMed ID: 23533265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
    Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
    Front Oncol; 2014; 4():58. PubMed ID: 24744988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.
    Yu B; Wang J; He C; Wang W; Tang J; Zheng R; Zhou C; Zhang H; Fu Z; Li Q; Xu J
    Exp Ther Med; 2017 Jul; 14(1):831-840. PubMed ID: 28673007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
    Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
    Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
    Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
    Spigel DR; Reynolds C; Waterhouse D; Garon EB; Chandler J; Babu S; Thurmes P; Spira A; Jotte R; Zhu J; Lin WH; Blumenschein G
    J Thorac Oncol; 2018 May; 13(5):682-688. PubMed ID: 29518553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.